Feifei Qi

629 total citations
8 papers, 472 citations indexed

About

Feifei Qi is a scholar working on Oncology, Electrical and Electronic Engineering and Genetics. According to data from OpenAlex, Feifei Qi has authored 8 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Electrical and Electronic Engineering and 2 papers in Genetics. Recurrent topics in Feifei Qi's work include CAR-T cell therapy research (7 papers), Advancements in Semiconductor Devices and Circuit Design (3 papers) and Virus-based gene therapy research (2 papers). Feifei Qi is often cited by papers focused on CAR-T cell therapy research (7 papers), Advancements in Semiconductor Devices and Circuit Design (3 papers) and Virus-based gene therapy research (2 papers). Feifei Qi collaborates with scholars based in China and Japan. Feifei Qi's co-authors include Xin‐an Lu, Guangjun Nie, Yanping Ding, Rong Cai, Wenjing Wu, Jihui Hao, Yinlong Zhang, Jiayan Lang, Xiao Zhao and Tianjiao Ji and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Frontiers in Oncology.

In The Last Decade

Feifei Qi

8 papers receiving 468 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Feifei Qi China	8	333	197	166	96	89	8	472
Xiaoyang Zhang China	10	401 1.2×	192 1.0×	205 1.2×	52 0.5×	128 1.4×	22	637
Meijia Yang China	8	350 1.1×	122 0.6×	145 0.9×	53 0.6×	191 2.1×	11	561
John Mac United States	7	384 1.2×	175 0.9×	293 1.8×	44 0.5×	192 2.2×	9	641
Meena Kadapakkam United States	6	530 1.6×	260 1.3×	274 1.7×	74 0.8×	190 2.1×	7	847
Yongmei Ding China	9	257 0.8×	124 0.6×	178 1.1×	93 1.0×	97 1.1×	13	440
Xueru Song China	12	161 0.5×	188 1.0×	157 0.9×	39 0.4×	123 1.4×	22	537
Ali Hassanzadeh Iran	7	360 1.1×	140 0.7×	158 1.0×	24 0.3×	189 2.1×	12	543
Zachary Spencer Dunn United States	13	318 1.0×	136 0.7×	143 0.9×	39 0.4×	227 2.6×	19	495
Fabio Turatti Italy	9	149 0.4×	69 0.4×	191 1.2×	84 0.9×	75 0.8×	9	468
Sarah Nietzer Germany	11	344 1.0×	213 1.1×	162 1.0×	70 0.7×	115 1.3×	20	604

Countries citing papers authored by Feifei Qi

Since Specialization

Citations

This map shows the geographic impact of Feifei Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Qi more than expected).

Fields of papers citing papers by Feifei Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feifei Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Qi. The network helps show where Feifei Qi may publish in the future.

Co-authorship network of co-authors of Feifei Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Feifei Qi. A scholar is included among the top collaborators of Feifei Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feifei Qi. Feifei Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Wang, Ting, Ting He, Ru Feng, et al.. (2022). Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion. Frontiers in Oncology. 12. 854448–854448. 10 indexed citations

2.

Su, Tong, Zhitao Ying, Xin‐an Lu, et al.. (2020). The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients. Cryobiology. 96. 106–113. 10 indexed citations

3.

Zhao, Xiangyu, Junfang Yang, Xian Zhang, et al.. (2020). Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Molecular Therapy — Oncolytics. 18. 272–281. 82 indexed citations

4.

Wan, Wei, Ting He, Feifei Qi, et al.. (2019). Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Therapy. 26(7-8). 248–255. 18 indexed citations

5.

Ying, Zhitao, Xiaopei Wang, Wen Zheng, et al.. (2019). Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma. Molecular Therapy — Oncolytics. 15. 60–68. 117 indexed citations

6.

Lu, Peihua, Xin‐an Lu, Xian Zhang, et al.. (2018). Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.. Journal of Clinical Oncology. 36(15_suppl). 3041–3041. 12 indexed citations

7.

Ji, Tianjiao, Jiayan Lang, Jing Wang, et al.. (2017). Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy. ACS Nano. 11(9). 8668–8678. 197 indexed citations

8.

Qian, Liren, Dan Li, Lie Ma, et al.. (2016). The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cellular Immunology. 304-305. 49–54. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact